Innovative studies have demonstrated the feasibility of biodegradable microneedle patches incorporating GLP-1 analogs such as exenatide and liraglutide, achieving sustained glucose-lowering effects in preclinical models
[00:04:05] Emily Field: No one starts a GLP one medication, excited to be on it for the rest of their life
ACS Chem
For someone struggling with life-altering low blood sugar this was really difficult
Some you have likely heard of, like nausea, but others might be a little more surprising
[1] [5] While most GLP-1 medications are administered via subcutaneous injection (such as semaglutide, liraglutide, dulaglutide, or tirzepatide), with oral semaglutide (Rybelsus) as the only FDA-approved non-injectable option, transdermal patch delivery systems represent an emerging area of pharmaceutical development